Poseida Therapeutics (PSTX) Stock Forecast, Price Target & Predictions
PSTX Stock Forecast
Poseida Therapeutics stock forecast is as follows: an average price target of $10.00 (represents a 5.82% upside from PSTX’s last price of $9.45) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
PSTX Price Target
The average price target for Poseida Therapeutics (PSTX) is $10.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 5.82% upside from PSTX's last price of $9.45.
PSTX Analyst Ratings
According to 2 Wall Street analysts, Poseida Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PSTX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Poseida Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 02, 2024 | Edward Tenthoff | Piper Sandler | $10.00 | $9.31 | 7.41% | 5.82% |
| Jan 04, 2023 | H.C. Wainwright | $15.00 | $5.79 | 159.07% | 58.73% |
The latest Poseida Therapeutics stock forecast, released on Dec 02, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $10.00, which represents a 7.41% increase from the stock price at the time of the forecast ($9.31), and a 5.82% increase from PSTX last price ($9.45).
Poseida Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $10.00 | $10.00 | $10.00 |
| Last Closing Price | $9.45 | $9.45 | $9.45 |
| Upside/Downside | 5.82% | 5.82% | 5.82% |
In the current month, the average price target of Poseida Therapeutics stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 5.82% increase as opposed to Poseida Therapeutics's last price of $9.45. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Oct 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Poseida Therapeutics's last stock rating was published by Piper Sandler on Dec 02, 2024. The company Downgrade its PSTX rating from "Overweight" to "Neutral".
Poseida Therapeutics Financial Forecast
Poseida Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $25.00M | $9.35M | $20.01M | $10.34M | $9.92M | $116.31M | $2.70M | $1.44M | $31.24 | - |
| Avg Forecast | $93.35M | $90.66M | $88.05M | $85.51M | $7.50M | $7.50M | $7.50M | $7.50M | $21.25M | $16.25M | $15.42M | $11.67M | $6.65M | $18.87M | $6.78M | $9.38M | $61.69M | $1.25M | $1.40M | $478.33K | $23.13M | $3.63M |
| High Forecast | $115.88M | $112.54M | $109.30M | $106.15M | $9.31M | $9.31M | $9.31M | $9.31M | $28.33M | $20.17M | $15.42M | $14.48M | $8.26M | $18.87M | $8.42M | $11.64M | $76.58M | $1.25M | $1.40M | $478.33K | $23.13M | $4.35M |
| Low Forecast | $77.25M | $75.03M | $72.87M | $70.77M | $6.21M | $6.21M | $6.21M | $6.21M | $14.17M | $13.45M | $15.42M | $9.66M | $5.50M | $18.87M | $5.61M | $7.76M | $51.05M | $1.25M | $1.40M | $478.33K | $23.13M | $2.90M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.76% | 0.50% | 2.95% | 1.10% | 0.16% | 93.04% | 1.93% | 3.00% | 0.00% | - |
Poseida Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $11.67M, with a low forecast of $9.66M, and a high forecast of $14.48M. PSTX's average Quarter revenue forecast represents a -53.32% decrease compared to the company's last Quarter revenue of $25.00M (Dec 23).
Poseida Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-46.18M | $-36.22M | $-27.86M | $-36.82M | $-31.05M | $73.79M | $-40.23M | $-55.77M | $123.80K | $-29.09M |
| Avg Forecast | $-7.84M | $-7.62M | $-7.40M | $-7.19M | $-630.25K | $-630.25K | $-630.25K | $-630.25K | $-1.79M | $-1.37M | $-1.30M | $-980.40K | $-558.83K | $-1.59M | $-569.75K | $-787.82K | $-5.18M | $-109.48K | $-122.62K | $-36.25M | $-2.03M | $-14.66M |
| High Forecast | $-6.49M | $-6.30M | $-6.12M | $-5.95M | $-521.59K | $-521.59K | $-521.59K | $-521.59K | $-1.19M | $-1.13M | $-1.30M | $-811.36K | $-462.48K | $-1.59M | $-471.52K | $-651.99K | $-4.29M | $-109.48K | $-122.62K | $-29.00M | $-2.03M | $-11.73M |
| Low Forecast | $-9.74M | $-9.46M | $-9.18M | $-8.92M | $-782.38K | $-782.38K | $-782.38K | $-782.38K | $-2.38M | $-1.70M | $-1.30M | $-1.22M | $-693.72K | $-1.59M | $-707.28K | $-977.98K | $-6.44M | $-109.48K | $-122.62K | $-43.50M | $-2.03M | $-17.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 82.64% | 22.85% | 48.89% | 46.74% | 5.99% | -673.97% | 328.12% | 1.54% | -0.06% | 1.98% |
1 analysts predict PSTX's average Quarter EBITDA for Dec 22 to be $-5.18M, with a high of $-4.29M and a low of $-6.44M. This is -107.03% lower than Poseida Therapeutics's previous annual EBITDA (Sep 22) of $73.79M.
Poseida Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-23.99M | $-31.78M | $-27.46M | $-40.21M | $-33.32M | $70.41M | $-44.53M | $-59.15M | $17.73M | $-30.43M |
| Avg Forecast | $-22.80M | $-22.42M | $-22.05M | $-21.52M | $-37.16M | $-45.71M | $-49.60M | $-45.81M | $-32.42M | $-41.01M | $-39.95M | $-41.25M | $-37.91M | $-28.81M | $-51.86M | $-44.25M | $16.67M | $-63.27M | $-73.94M | $-37.74M | $-33.70M | $-15.38M |
| High Forecast | $-17.69M | $-17.40M | $-17.11M | $-16.70M | $-28.83M | $-35.47M | $-38.48M | $-28.27M | $-25.22M | $-31.82M | $-30.99M | $-32.01M | $-16.85M | $-22.35M | $-40.24M | $-34.34M | $21.90M | $-63.27M | $-73.94M | $-30.19M | $-33.70M | $-12.30M |
| Low Forecast | $-29.95M | $-29.46M | $-28.97M | $-28.27M | $-48.82M | $-60.06M | $-65.17M | $-63.36M | $-45.03M | $-53.87M | $-52.48M | $-54.20M | $-52.66M | $-37.85M | $-68.13M | $-58.14M | $12.93M | $-63.27M | $-73.94M | $-45.28M | $-33.70M | $-18.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.63% | 1.10% | 0.53% | 0.91% | -2.00% | -1.11% | 0.60% | 1.57% | -0.53% | 1.98% |
Poseida Therapeutics's average Quarter net income forecast for Dec 22 is $16.67M, with a range of $12.93M to $21.90M. PSTX's average Quarter net income forecast represents a -76.33% decrease compared to the company's last Quarter net income of $70.41M (Sep 22).
Poseida Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.86M | $8.09M | $8.68M | $11.81M | $9.37M | $9.39M | $9.24M | $9.55M | $-26.27K | $4.24M |
| Avg Forecast | $74.98M | $72.82M | $70.72M | $68.68M | $6.02M | $6.02M | $6.02M | $6.02M | $17.07M | $13.05M | $12.38M | $9.37M | $5.34M | $15.15M | $5.45M | $7.53M | $49.55M | $1.00M | $1.12M | $384.22K | $18.58M | $2.14M |
| High Forecast | $93.08M | $90.40M | $87.79M | $85.26M | $7.48M | $7.48M | $7.48M | $7.48M | $22.76M | $16.20M | $12.38M | $11.63M | $6.63M | $15.15M | $6.76M | $9.35M | $61.51M | $1.00M | $1.12M | $384.22K | $18.58M | $2.57M |
| Low Forecast | $62.05M | $60.27M | $58.53M | $56.84M | $4.99M | $4.99M | $4.99M | $4.99M | $11.38M | $10.80M | $12.38M | $7.76M | $4.42M | $15.15M | $4.51M | $6.23M | $41.01M | $1.00M | $1.12M | $384.22K | $18.58M | $1.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.66% | 0.53% | 1.59% | 1.57% | 0.19% | 9.35% | 8.21% | 24.85% | -0.00% | 1.98% |
Poseida Therapeutics's average Quarter SG&A projection for Mar 24 is $9.37M, based on 1 Wall Street analysts, with a range of $7.76M to $11.63M. The forecast indicates a 5.77% rise compared to PSTX last annual SG&A of $8.86M (Dec 23).
Poseida Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 17 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.00 | $-0.47 | $-0.39 | $0.92 | $-0.71 | $-0.95 | $0.28 | $-0.53 |
| Avg Forecast | $-0.23 | $-0.23 | $-0.22 | $-0.22 | $-0.38 | $-0.47 | $-0.51 | $-0.47 | $-0.33 | $-0.42 | $-0.41 | $-0.42 | $-0.39 | $-0.29 | $-0.53 | $-0.45 | $0.17 | $-0.65 | $-0.76 | $-0.73 | $-0.35 | $-1.15 |
| High Forecast | $-0.18 | $-0.18 | $-0.17 | $-0.17 | $-0.29 | $-0.36 | $-0.39 | $-0.29 | $-0.26 | $-0.32 | $-0.32 | $-0.33 | $-0.17 | $-0.23 | $-0.41 | $-0.35 | $0.22 | $-0.65 | $-0.76 | $-0.73 | $-0.35 | $-1.15 |
| Low Forecast | $-0.30 | $-0.30 | $-0.29 | $-0.29 | $-0.50 | $-0.61 | $-0.66 | $-0.65 | $-0.46 | $-0.55 | $-0.53 | $-0.55 | $-0.54 | $-0.39 | $-0.69 | $-0.59 | $0.13 | $-0.65 | $-0.76 | $-0.73 | $-0.35 | $-1.15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 1.04% | -2.30% | -1.41% | 0.93% | 1.31% | -0.81% | 0.46% |
According to 1 Wall Street analysts, Poseida Therapeutics's projected average Quarter EPS for Dec 22 is $0.17, with a low estimate of $0.13 and a high estimate of $0.22. This represents a -81.56% decrease compared to PSTX previous annual EPS of $0.92 (Sep 22).
Poseida Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| CUE | Cue Biopharma | $1.06 | $3.00 | 183.02% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| DYN | Dyne Therapeutics | $26.16 | $49.00 | 87.31% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| PSTX | Poseida Therapeutics | $9.50 | $10.00 | 5.26% | Buy |